

Ameliorative Effect of Adenosine on Hypoxia-Reoxygenation Injury in LLC-PK₁, a Porcine Kidney Cell Line

Tsutomu Yonehana and Munekazu Gemba*

Division of Pharmacology, Osaka University of Pharmaceutical Sciences, Nasahara, Takatsuki, Osaka 569–1094, Japan

Received November 16, 1998 Accepted March 19, 1999

ABSTRACT—We studied the effects of adenosine on injury caused by hypoxia and reoxygenation in LLC-PK₁ cells. Lactate dehydrogenase and γ -glutamyltranspeptidase were released from cells exposed to hypoxia for 6 hr and then reoxygenation for 1 hr. The addition of adenosine at 100 μ M to the medium before hypoxia began significantly decreased enzyme leakage into medium during both hypoxia and reoxygenation. The adenosine A₁-receptor agonist, *R*(–)-*N*⁶-(2-phenylisopropyl)adenosine (R-PIA), at the concentration of 100 μ M, did not affect enzyme release, but the adenosine A₂-receptor agonist 2-*p*-[2-carboxyethyl]phenethyl-amino-5′-*N*-ethylcarboxamido-adenosine hydrochloride (CGS 21680) at the concentration of 100 nM, suppressed the injury caused by hypoxia and reoxygenation. There were decreases in cAMP contents and ATP levels in LLC-PK₁ cells injured by hypoxia and reoxygenation. Adenosine (100 μ M) restored ATP levels in the cells during reoxygenation. With adenosine, the intracellular cAMP level was increased prominently during reoxygenation. These results suggest that adenosine protects LLC-PK₁ cells from injury caused by hypoxia and reoxygenation by increasing the intracellular cAMP level via adenosine A₂ receptor.

Keywords: Acute renal failure, Hypoxia and reoxygenation, Adenosine A₂ receptor, Cyclic AMP, LLC-PK₁ cell

Renal proximal tubules, especially their second segments (S₂), may function abnormally when reperfusion of an ischemic kidney causes acute renal failure (1–3). The development of in vitro methods using modern cell culture techniques has enabled us to understand the cellular mechanisms of ischemia-reperfusion injury under in vivo conditions. LLC-PK₁ cells, derived from pig kidney, have characteristics of proximal tubules, and MDCK cells, derived from canine kidney, have characteristics of distal tubular and collecting duct epithelia. Exposure of LLC-PK₁ cells to hypoxia and reoxygenation increases the leakage of lactate dehydrogenase (LDH) from the cells, but MDCK cells treated in the same way are not injured (4). Lipid peroxidation mediated by oxygen radicals causes reperfusion injury in ischemic kidneys (5). Injury by hypoxia and reoxygenation of LLC-PK₁ cells is suppressed by an antioxidant and free radical scavengers, suggesting that oxidative stress is involved in the injury in vitro as well as in vivo (4).

Adenosine administered helps to prevent injury during

postischemic reperfusion of the heart, and this effect may be mediated by adenosine A₁ receptors (6, 7). In the kidney, adenosine releases renin, contributes to the production of erythropoietin, and decreases the GFR; afferent and efferent arterioles and tubules have adenosine receptors (8). An adenosine A₁-receptor antagonist attenuates the renal injury caused by cisplatin in rats (9). LLC-PK₁ cells express both adenosine A₁ and A₂ receptors (10). In this study, we examined the effects of adenosine and two receptor agonists on injury caused by hypoxia and reoxygenation using LLC-PK₁ cells.

MATERIALS AND METHODS

Chemicals

An adenosine A₂-receptor agonist, 2-*p*-[2-carboxyethyl]phenethyl-amino-5′-*N*-ethylcarboxamido-adenosine hydrochloride (CGS 21680) (11), and a phosphodiesterase inhibitor, 4-([3-butoxy-4-methoxyphenyl]methyl)-2-imidazolidinone (Ro 20-1724), were purchased from Research Biochemicals, Inc. (Natick, MA, USA). *R*(–)-*N*⁶-(2-phenylisopropyl)adenosine (R-PIA), an adenosine

* To whom correspondence should be addressed.

A₁-receptor agonist (11, 12), Dulbecco's modified Eagle medium (DMEM), HEPES and NaHCO₃ were purchased from Sigma Chemical Co. (St. Louis, MO, USA). *L*-Glutamine and DMEM were from ICN Biomedicals, Inc. (Costa Mesa, CA, USA) and Nissui Pharmaceutical Co., Ltd. (Tokyo), respectively. All other chemicals used were of the highest purity available commercially.

Cell culture

LLC-PK₁ cells were obtained from the American Type Culture Collection (Rockville, MD, USA), and grown in DMEM containing 5.55 mM glucose, 5% fetal bovine serum and 10 mM HEPES. The cells were subcultured every 4 days.

Hypoxia and reoxygenation

We used cells that had grown into a confluent monolayer for the experiments with hypoxia and reoxygenation as described elsewhere (4). In brief, the medium was removed and the cells were washed two times with DMEM base, which lacks glucose and serum. The cells were exposed to hypoxic conditions in a GasPak Pouch™ (Becton Dickinson and Co., Cockeysville, MD, USA) in which the oxygen concentration was less than 2%. After 6 hr of hypoxia, the cells were put in a humidified atmosphere of 95% air and 5% CO₂ for 1 hr in the DMEM base to which glucose was added at the beginning of reoxygenation. Adenosine-receptor agonists and phosphodiesterase inhibitor were added to the medium just before the beginning of hypoxia.

Evaluation of cell injury

After 7 hr of treatment, the medium was centrifuged at 5°C for 10 min at 1,500 × *g*. The activities of LDH and γ -glutamyltranspeptidase (γ -GTP) released into the medium were assayed with commercial kits (Wako Pure Chemical Industries, Ltd., Osaka) and used as indices of cell injury.

One milliliter of ice-cold 2% trichloroacetic acid was added to the cells after centrifugation, and the cells were scraped and sonicated for 30 sec. The cell homogenate was centrifuged at 2,000 × *g* for 15 min at 5°C. The supernatant was assayed for ATP by the luciferin-luciferase method of Kimmich et al. (13) with an ATP photometer (model 2000; JRB Inc., La Jolla, CA, USA). The sediment was assayed for protein by the method of Bradford (14).

Measurement of intracellular cyclic AMP

For the assay of intracellular cAMP, the cells were sonicated in ice-cold 6% perchloric acid for 30 sec. The cell homogenate was centrifuged at 1,500 × *g* for 15 min at 5°C. The supernatant was neutralized with appropriate

amounts of 81 mM KOH and 0.54 M K₂HPO₄ and frozen at -80°C until they were assayed for cAMP with a commercial kit (Yamasa Corp., Tokyo).

Assay of antioxidation by adenosine

The antioxidative activity of 100 μ M adenosine was tested in terms of its inhibition of the reduction of ferricytochrome C to ferrocyanochrome C caused by superoxide anions produced in the reaction of hypoxanthine and xanthine oxidase. The reaction mixture contained 7 mM hypoxanthine, 9 mM cytochrome C and 2.2 units of xanthine oxidase. The formation of ferrocyanochrome C was estimated by monitoring of the absorbance at 560 nm.

Statistical analyses

Results are expressed as means \pm S.D. ANOVA followed by Fisher's procedure was used to evaluate the statistical significance of differences.

RESULTS

Effects of adenosine on cell injury

LDH, a cytoplasmic enzyme, was released into the medium during the 6 hr of hypoxia and more was released during the hour of reoxygenation (Fig. 1). The addition of adenosine before hypoxia suppressed the




Fig. 1. Effects of adenosine on LDH and γ -GTP leakage from LLC-PK₁ cells exposed to 7 hr of normoxia (C), 6 hr of hypoxia (H) or 6 hr of hypoxia followed by 1 hr of reoxygenation (R). Closed columns show leakage of enzymes with no adenosine in the medium, and open columns show the leakage in the presence of 100 μ M adenosine. Values are means \pm S.D. of at least three experiments. **P* < 0.01, compared with the corresponding "C" and #*P* < 0.01, compared with the corresponding "H" without adenosine in the medium.

release of LDH during hypoxia. Adenosine helped to prevent more leakage of LDH during reoxygenation. The luminal surface of a LLC-PK₁ monolayer cultured on flat culture dishes was exposed directly to the medium. γ -GTP activity, which binds to the brush border membrane, was monitored to assess luminal membrane function. γ -GTP was also released from cells exposed to 6 hr of hypoxia and such release was accelerated by the reoxygenation. The release of γ -GTP during both treatments was also depressed with adenosine. ATP in the cells decreased during hypoxia and then returned to 80% of the control level during reoxygenation (Fig. 2). Adenosine had no effect on the decrease in the cellular ATP after hypoxia, but increased the rate for the return of the ATP level toward the base line during reoxygenation.

Radical scavenging by adenosine

Adenosine did not quench superoxide anion radicals generated in the reaction of hypoxanthine catalyzed by xanthine oxidase (data not shown).

Effects of adenosine receptor agonists on cell injury

R-PIA had no effect on LDH leakage from LLC-PK₁ cells exposed to hypoxia and reoxygenation (Fig. 3). However, after addition of CGS 21680 at the concentration of 100 nM, there was attenuation of cell injury as assessed by LDH leakage from the cells. CGS 21680 also lessened γ -GTP leakage induced by hypoxia and reoxygenation (data not shown). Neither of the adenosine-receptor agonists affected the activities of LDH and γ -GTP released from LLC-PK₁ cells cultured under normoxic condition (data not shown).




Fig. 2. Effects of hypoxia and reoxygenation with and without adenosine on the ATP concentration in LLC-PK₁ cells. Closed columns show ATP concentrations without adenosine, and open columns show ATP concentrations with 100 μ M adenosine. Values are means \pm S.D. of at least three experiments. *P < 0.01, compared with the corresponding control.

Effects of adenosine on intracellular cAMP

The intracellular cAMP level was decreased after hypoxia and reoxygenation (Fig. 4). We tried to delineate whether adenosine increases the intracellular cAMP level in the presence of a phosphodiesterase inhibitor, Ro 20-1724, in the medium. Adenosine remarkably increased cAMP level in the cells exposed to hypoxia and reoxygenation.




Fig. 3. Effect of adenosine-receptor agonists on LDH leakage from LLC-PK₁ cells exposed to hypoxia and then reoxygenation. Adenosine (ADO, 100 μ M), an adenosine A₁-receptor agonist, *R*(-)-*N*⁶-(2-phenylisopropyl)adenosine (R-PIA, 100 μ M), or an A₂-receptor agonist (CGS 21680, 10 nM or 100 nM) was added to the medium just before hypoxia began. Values show means \pm S.D. of at least three experiments. *P < 0.01, compared with results when no additions were made.




Fig. 4. Effects of hypoxia and reoxygenation with adenosine with or without a phosphodiesterase inhibitor on the cAMP concentration in LLC-PK₁ cells. The cells were exposed to 7 hr of normoxia (Control) or 6 hr of hypoxia followed by 1 hr of reoxygenation. Adenosine (ADO, 100 μ M), the phosphodiesterase inhibitor 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone (Ro 20-1724, or Ro: 200 μ M), or both were added to the medium just before hypoxia began. Values show means \pm S.D. of at least three experiments. *P < 0.01, compared with the control.

DISCUSSION

Ischemia-followed by reperfusion of kidneys depletes ATP (15). Hypoxic cell injury causes in vitro decreases in the ATP level (4, 16) and the oxidative phosphorylation activity (17) in proximal tubular cells. ATP depletion, especially in proximal tubular cells which depend on oxidative phosphorylation for energy supply, leads to an intracellular disturbance of chloride and calcium in hypoxic injury of the cells (16, 17). The chloride channel blockers provide marked cytoprotection against the hypoxia-induced release of LDH, a marker for cellular injury, but do not associate with preservation of cell ATP content (16). Adenosine reduced the release of LDH and γ -GTP from hypoxic LLC-PK₁ cells. The reduction in both enzyme releases was not accompanied by protection against hypoxia-induced ATP decrease. Hypoxia-induced membrane damage as measured by the release of the enzymes LDH and γ -GTP from hypoxic tubule is a marker of advanced or late cellular injury as compared with ATP depletion in terms of onset in cellular injury. The pattern of cytoprotection by adenosine resembles the pattern of that by chloride channel blockers, suggesting that adenosine blocks a late event in the process of hypoxic injury, including LDH and γ -GTP release, but does not prevent early damage to cellular ATP content. In contrast to hypoxic injury, adenosine accelerates the return to the base line of the ATP concentration in isolated tubules during reoxygenation (18). In LLC-PK₁ cells during reoxygenation, adenosine had the same effect on the recovery of ATP level in the present study. In addition, adenosine decreased the cell injury taking place during reoxygenation, as assessed by the decreased leakage of LDH and γ -GTP. These results suggest that adenosine protects LLC-PK₁ cells from reoxygenation injury at least in part via the accelerated recovery of the ATP level. Antioxidants attenuate injury of LLC-PK₁ cells caused by reoxygenation (4). Some preliminary experiments in our laboratory have shown that when electron spin resonance (ESR) is used to detect free radicals in LLC-PK₁ cells, oxygen radicals are increased in the cells exposed to hypoxia followed by reoxygenation, and such an increase in oxygen radicals is lowered by adenosine. Recently, Yokoi et al. (19) have found that adenosine scavenges hydroxyl radicals at a concentration of 5 mM, fifty times the concentration used in our study. Adenosine itself at a concentration used in the present study had no scavenging action, so its effect on LLC-PK₁ cell injury probably does not arise from its being an antioxidant.

Adenosine receptors have been classified into subtypes A₁, A_{2a}, A_{2b} and A₃ (20). The A₁ receptor participates in the attenuation by adenosine on cardiac injury caused by ischemia and reperfusion (6, 7). The A₂ receptor is

involved in the suppression of the generation by human neutrophils of superoxide anions (21). The kidney expresses the genes of adenosine receptors (22) and adenosine receptors exist in the kidney (8). LLC-PK₁ cells express both adenosine A₁ and A₂ receptors, and the majority of stimulatory adenosine A₂ receptors are in the cell apical surfaces (10). R-PIA at the concentrations of 1 to 10 μ M activates adenosine A₁ receptors (23, 24). R-PIA at up to 100 μ M did not affect enzyme release from LLC-PK₁ cells exposed to hypoxia and reoxygenation, but CGS 21680 at 100 nM depressed cell injury caused by such treatment. These two results suggest that the ameliorative effect on such injury in LLC-PK₁ cells is probably mediated not by adenosine A₁ but by adenosine A₂ receptors.

Adenosine A₂ receptors stimulate adenylate cyclase activity in isolated tubules of the rabbit renal cortex (25). Our results indicate that adenosine increases cAMP level by activating adenosine A₂ receptors, and the increment of cAMP levels attenuates hypoxia and reoxygenation injury in LLC-PK₁ cells. *N*⁶,*O*²-dibutyryl cAMP, a cAMP derivative that can permeate cell membranes, attenuates the renal injury caused by ischemia and reperfusion in rats (26). Such injury is mediated by the generation of oxygen radicals that induce lipid peroxidation in rat kidneys (5). In LLC-PK₁ cells as well, reactive oxygen species participate in the cell injury caused by hypoxia and reoxygenation (4). Nosaka et al. (27) have found that an increase in intracellular cAMP inhibits the production of reactive oxygen metabolites in cultured rat mesangial cells.

In the present study, we demonstrated the ameliorative effect of adenosine at a concentration of 100 μ M on hypoxia-reoxygenation injury in LLC-PK₁ cells. Such injury was significantly attenuated even by a much lower concentration of adenosine at 10 μ M which achieved a concentration near to a clinical one in blood plasma (data not shown). A further study of the protective effect of adenosine on hypoxia and reoxygenation injury in LLC-PK₁ cells should be conducted to understand the in vivo effect of adenosine on acute renal failure induced by ischemia and reperfusion for its therapeutic application in the fields of clinical medicine.

In conclusion, adenosine attenuated the injury in LLC-PK₁ cells exposed to hypoxia and reoxygenation. That effect was accompanied by an increase in cAMP levels and by a rapid but slight return of the ATP levels to the base line during reoxygenation. The stimulation of adenosine A₂ receptors is the primary mechanism of the ameliorative effect of adenosine on cell injury during reoxygenation after hypoxia in LLC-PK₁ cells.

Acknowledgment

We thank Ms. Caroline Latta for reading the manuscript.

REFERENCES

- 1 Tanner GA, Sloan KL and Sophasan S: Effects of renal artery occlusion on kidney function in the rat. *Kidney Int* **4**, 377–389 (1973)
- 2 Madias NE and Harrington JT: Postischemic acute renal failure. In *Acute Renal Failure*, Edited by Brenner BM and Lazarus JM, pp 235–251, WB Saunders Co, Philadelphia (1983)
- 3 Kotowski A, Ruhrberg A and Kaufmann P: The influence of hypoxic cell-free perfusion and ischemia on cell morphology in the proximal tubular S₂-segment of the rat kidney. *Virchows Arch B Cell Pathol* **59**, 329–337 (1990)
- 4 Yonehana T and Gemba M: Hypoxia and reoxygenation-induced injury of renal epithelial cells: Effect of free radical scavengers. *Jpn J Pharmacol* **68**, 231–234 (1995)
- 5 Paller MS, Hoidal JR and Ferris TF: Oxygen free radicals in ischemic acute renal failure in the rat. *J Clin Invest* **74**, 1156–1164 (1984)
- 6 Lasley RD and Mentzer RM Jr: Adenosine improves recovery of postischemic myocardial function via an adenosine A₁ receptor mechanism. *Am J Physiol* **263**, H1460–H1465 (1992)
- 7 Lee Y-M, Sheu J-R and Yen M-H: BN-063, a newly synthesized adenosine A₁ receptor agonist, attenuates myocardial reperfusion injury in rats. *Eur J Pharmacol* **279**, 251–256 (1995)
- 8 Spielman WS and Areund LJ: Adenosine receptors and signaling in the kidney. *Hypertension* **17**, 117–130 (1991)
- 9 Nagashima K, Kusaka H and Karasawa A: Protective effects of KW-3902, an adenosine A₁-receptor antagonist, against cisplatin-induced acute renal failure in rats. *Jpn J Pharmacol* **67**, 349–357 (1995)
- 10 LeVier DG, McCoy DE and Spielman WS: Functional localization of adenosine receptor-mediated pathways in the LLC-PK₁ renal cell line. *Am J Physiol* **263**, C729–C735 (1992)
- 11 Collis MG and Hourani SMO: Adenosine receptor subtypes. *Trends Pharmacol Sci* **14**, 360–366 (1993)
- 12 Stiles GL: Adenosine receptors. *J Biol Chem* **267**, 6451–6454 (1992)
- 13 Kimmich GA, Randles J and Brand JS: Assay of picomole amounts of ATP, ADP and AMP using the luciferase enzyme system. *Anal Biochem* **69**, 187–206 (1975)
- 14 Bradford MM: A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**, 248–254 (1976)
- 15 Karasawa A and Kubo K: Protection by benidipine hydrochloride (KW-3049), a calcium antagonist, of ischemic kidney in rats via inhibitions of Ca-overload, ATP-decline and lipid peroxidation. *Jpn J Pharmacol* **52**, 553–562 (1990)
- 16 Reeves WB: Effects of chloride channel blockers on hypoxic injury in rat proximal tubules. *Kidney Int* **51**, 1529–1534 (1997)
- 17 Peters SMA, Tijssen MJH, Van Os CH, Wetzels JFM and Bindels RJM: Hypoxia decreases calcium influx into rat proximal tubules. *Kidney Int* **53**, 703–708 (1998)
- 18 Cadnapaphornchai P, Kellner D, Golembieski A and McDonald FD: Roles of adenosine and theophylline on the recovery of adenine nucleotides in postischemic cultured renal tubular cells. *J Pharmacol Exp Ther* **257**, 774–780 (1991)
- 19 Yokoi I, Toma J, Liu J, Kabuto H and Mori A: Adenosines scavenged hydroxyl radicals and prevented posttraumatic epilepsy. *Free Radic Biol Med* **19**, 473–479 (1995)
- 20 Dalziel HH and Westfall DP: Receptors for adenine nucleotides and nucleosides: Subclassification, distribution, and molecular characterization. *Pharmacol Rev* **46**, 449–466 (1994)
- 21 Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G and Hirschhorn R: Adenosine: A physiologic modulator of superoxide anion generated by human neutrophils. Adenosine acts via an A₂ receptor on human neutrophils. *J Immunol* **135**, 1366–1371 (1985)
- 22 Weaver DR and Reppert SM: Adenosine receptor gene expression in rat kidney. *Am J Physiol* **263**, F991–F995 (1992)
- 23 Boehm S: Noradrenaline release from rat sympathetic neurons evoked by P₂-purinoceptor activation. *Naunyn Schmiedeberg Arch Pharmacol* **350**, 454–458 (1994)
- 24 Clark KI and Barry SR: Aminophylline enhances resting Ca²⁺ concentrations and twitch tension by adenosine receptor blockade in *Rana pipiens*. *J Physiol (Lond)* **481**, 129–137 (1994)
- 25 Freissmuth M, Nanoff C, Tüisel E and Schuetz W: Stimulation of adenylate cyclase activity via A₂-adenosine receptors in isolated tubules of the rabbit renal cortex. *Eur J Pharmacol* **138**, 137–140 (1987)
- 26 Koiwai T, Oguchi H, Terashima M, Yanagisawa Y, Higuchi M and Furuta S: Beneficial effect of dibutyryl cyclic AMP (DBcAMP) on ischemic acute renal failure in the rat. *Renal Failure* **14**, 461–465 (1992)
- 27 Nosaka K, Takahashi T, Miyanooshita A, Nishi T, Suzuki K, Kurokawa K and Endou H: Effect of adenosine on phorbol myristate acetate induced-reactive oxygen metabolite production in cultured mesangial cells. *Free Radic Biol Med* **20**, 151–155 (1996)